Results 101 to 110 of about 516,619 (288)
Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer
International Journal of Cancer, EarlyView.ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue +6 more
wiley +1 more source
iNew Medicine, EarlyView.ABSTRACT Human papillomavirus (HPV) is a double‐stranded DNA virus that infects human skin and mucosal tissues exclusively. The German scientist Harald zur Hausen was awarded the 2008 Nobel Prize in Physiology or Medicine for his discovery of the link between HPV infection and cervical cancer.
Fang Zhu +5 more
wiley +1 more source
iNew Medicine, EarlyView.ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid +4 more
wiley +1 more source
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies
, 2016 With the development of molecular cloning technology and the deep understanding of antibody engineering, there are diverse bispecific antibody formats from which to choose to pursue the optimal biological activity and clinical purpose.
Fa Yang, Weijun Qin, Weihong Wen
core +1 more source
Mass Spectrometry Reviews, EarlyView.ABSTRACT Top‐down proteomics (TDP) characterizes proteoforms in cells, tissues, and biofluids, in discovery mode and on a global scale, requiring analytical tools with high peak capacity for proteoform separation and high sensitivity for proteoform detection, given the extremely high proteoform complexity and wide proteoform concentration dynamic range.
Guijie Zhu +5 more
wiley +1 more source
Bispecific antibodies: Strategies, considerations and challenges [PDF]
, 2016 Bispecific antibodies (BsAbs) are moving mainstream as therapeutics with currently two bispecific antibodies approved and about 30 in clinical development.
Spiess, Christoph
core +1 more source
Advanced ScienceB‐cell lymphomas are hematologic malignancies characterized by poor prognoses. Immunotherapy has revolutionized B‐cell lymphoma treatment by harnessing immune effector cells, but current therapeutic strategies face limitations: suboptimal ...
Yefeng Shen +12 more
doaj +1 more source
AntibodiesBispecific antibodies have gained increasing popularity as therapeutics as they enable novel activities that cannot be achieved with monospecific antibodies.
Yinghui Rong +5 more
doaj +1 more source
Organoid Coculture Models for Cancer Research and Immunotherapy
Med Research, EarlyView.This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang +9 more
wiley +1 more source
Development of Bispecific Antibody Targeting Human IL-17A and IL-6
AntibodiesBackground/Objectives: Antibodies are a rapidly expanding field in drug discovery, but their monospecificity limits therapeutic applications, particularly in complex inflammatory diseases.
Beata Pamuła +13 more
doaj +1 more source